Study of Natalizumab in Relapsed/Refractory Multiple Myeloma
NCT00675428
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
6
Enrollment
INDUSTRY
Sponsor class
Stopped
Sponsor decision due to low enrollment and not safety concerns.
Conditions
Multiple Myeloma
Interventions
DRUG:
BG00002 (natalizumab)
Sponsor
Biogen